Glaukos Corp
NYSE:GKOS
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
74.67
160.58
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Glaukos Corp
NYSE:GKOS
|
6.8B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
187.1B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
184.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
139.3B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.2B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
129.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
55.2B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.9B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.5B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Glaukos Corp
Glance View
Founded in 1998, Glaukos Corporation has carved a niche within the highly specialized arena of ophthalmic medical technology. Enveloped in the nuances of eye health, Glaukos initially set its sights on transforming the treatment of glaucoma, a prevalent yet often devastating eye condition. The company pioneered the development of minimally invasive surgical devices, introducing the iStent, which offers a less invasive procedure compared to traditional glaucoma surgeries. This implantable device works by enhancing the natural outflow of fluid from the eye, ultimately reducing intraocular pressure, a key factor in managing glaucoma. Glaukos succeeded where many had faltered by coupling sophisticated technology with a deep understanding of its ophthalmologist customer base, facilitating smoother surgical processes and better patient outcomes. The business model of Glaukos is deeply intertwined with continuous innovation and robust partnerships with healthcare professionals. Revenue primarily stems from the sale of its flagship products—devices and systems designed for both glaucoma treatment and other corneal health therapies. The company achieves this through a combination of direct sales and strategic global partnerships, expanding its market reach beyond domestic borders. Furthermore, Glaukos invests significantly in research and development, extending its portfolio and venturing into adjacent fields like corneal disorders. This strategy not only secures its position as an industry leader but also catalyzes sustainable growth by addressing broader aspects of ophthalmic care, thus ensuring a steady stream of revenue flows as they remain at the cutting edge of eye healthcare solutions.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Glaukos Corp is -18.8%, which is above its 3-year median of -33.4%.
Over the last 3 years, Glaukos Corp’s Operating Margin has increased from -33.9% to -18.8%. During this period, it reached a low of -43.3% on Mar 31, 2023 and a high of -18.8% on Sep 30, 2025.